IBA Molecular Imaging

IBA Molecular Imaging was a commercial-stage nuclear medicine and radiopharmaceutical company focused on molecular imaging products and services, primarily across PET and SPECT. The company developed, manufactured, and distributed diagnostic radiopharmaceuticals and related supporting services for hospitals, radiopharmacies, and imaging centers worldwide. It operated a global manufacturing and distribution network and served customers across Europe, Asia, and other international markets. In January 2017, IBA Molecular Imaging completed the acquisition of Mallinckrodt Nuclear Imaging, and the combined business was subsequently rebranded as Curium. As a result, IBA Molecular Imaging no longer operates as an independent active company brand.